Brexit and the delay in the supply of medicines

Earlier this year, the Brexit Health Alliance published a paper calling on both the UK and EU to put patients first.

It warned that unless a deal can be reached, medicines and medical technologies could be delayed or, in extreme cases, become unavailable to patients.

The Alliance is concerned that if a decision can’t be reached regarding the future co-operation between the UK and the EU on the regulation and trade of medicines and medical devices that up to 120,000 prostate cancer patients throughout Europe could be affected.

Another area at risk is the future of research into new medicines and medical technologies. Without a plan in place, UK and EU patients could lose out on access to the best treatments and medical devices.

Are you concerned about the impact of Brexit? 
You can find below what the M3 Global Research community answered to this question.

Let us hear your opinion on this by signing up to receive the Monthly Pulse via email and to take part in paid medical studies.